Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemothe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmaceuticals (Basel)
Päätekijät: Bi, Jianling, Dixit, Garima, Zhang, Yuping, Devor, Eric J., Losh, Haley A., Newtson, Andreea M., Coleman, Kristen L., Santillan, Donna A., Maretzky, Thorsten, Thiel, Kristina W., Leslie, Kimberly K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8308742/
https://ncbi.nlm.nih.gov/pubmed/34358108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14070682
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia